Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle Cytotec

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA is negotiating with Searle to change the misoprostol label to reflect the potential for use in the Mifeprex pregnancy-termination regimen, FDA Commissioner Jane Henney, MD, told a House Commerce/Oversight Subcommittee hearing Oct. 3. Pharmacia subsidiary Searle issued a "Dear Health Care Provider" letter in August emphasizing that its gastric ulcer treatment is contraindicated for use in pregnant women and not approved for induction of labor or abortion. Danco Labs expects Mifeprex to be available in late October, and FDA presumably would want to have Cytotec labeling updated for Mifeprex's launc
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel